Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development.

Autor: Bialer M; Institute for Drug Research, Faculty of Medicine and David R. Bloom Center for Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Johannessen SI; National Center for Epilepsy, Sandvika, Norway.; Oslo University Hospital, member of the European Reference Network EpiCare, Oslo, Norway.; Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway., Koepp MJ; Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK., Perucca E; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia., Perucca P; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.; Bladin-Berkovic Comprehensive Epilepsy Program, Department of Neurology, Austin Health, Melbourne, Victoria, Australia.; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia., Tomson T; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., White HS; Department of Pharmacy, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washington, USA.

Publikováno v: Epilepsia [Epilepsia] 2024 Oct; Vol. 65 (10), pp. 2858-2882. Date of Electronic Publication: 2024 Aug 22.

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development.

Autor: Perucca E; Department of Medicine (Austin Health), Melbourne Brain Centre, The University of Melbourne, 245 Burgundy Street, Melbourne, VIC, 3084, Australia. emilio.perucca@unimelb.edu.au.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia. emilio.perucca@unimelb.edu.au., White HS; Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA., Bialer M; Faculty of Medicine, Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.; David R. Bloom Center for Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.

Publikováno v: CNS drugs [CNS Drugs] 2023 Sep; Vol. 37 (9), pp. 781-795. Date of Electronic Publication: 2023 Aug 21.

The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations.

Autor: Goldstein R; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Clinical Pharmacy, Faculty of Medicine, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Rabkin N; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Clinical Pharmacy, Faculty of Medicine, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Buchman N; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel., Jacobs AR; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel., Sandouka K; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel., Raccah B; Department of Clinical Pharmacy, Faculty of Medicine, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Cardiology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Fisher Negev T; Department of Clinical Pharmacy, Faculty of Medicine, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.; Department of Neurology, Faculty of Medicine, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel., Matok I; Department of Clinical Pharmacy, Faculty of Medicine, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Bialer M; School of Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Mt Scopus, 91905, Jerusalem, Israel. meirb@ekmd.huji.ac.il.; David R. Bloom Center for Pharmaceutical Sciences, Hebrew University of Jerusalem, Jerusalem, Israel. meirb@ekmd.huji.ac.il., Muszkat M; Department of Medicine, Faculty of Medicine, Hadassah Medical Center Mt. Scopus, Hebrew University of Jerusalem, Jerusalem, Israel.

Publikováno v: CNS drugs [CNS Drugs] 2024 May; Vol. 38 (5), pp. 399-408. Date of Electronic Publication: 2024 Mar 23.

Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development.

Autor: Bialer M; Institute for Drug Research, Faculty of Medicine, School of Pharmacy, and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel., Johannessen SI; National Center for Epilepsy, Sandvika, Norway.; Department of Pharmacology, Oslo University Hospital, Oslo, Norway., Koepp MJ; Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK., Levy RH; Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, Washington, USA., Perucca E; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia., Perucca P; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.; Bladin-Berkovic Comprehensive Epilepsy Program, Department of Neurology, Austin Health, Melbourne, Victoria, Australia.; Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia., Tomson T; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden., White HS; Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.

Publikováno v: Epilepsia [Epilepsia] 2022 Nov; Vol. 63 (11), pp. 2883-2910. Date of Electronic Publication: 2022 Aug 11.

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System.

Autor: Perucca E; Department of Medicine (Austin Health), The University of Melbourne, Melbourne, VIC, Australia. emilio.perucca@unimelb.edu.au.; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia. emilio.perucca@unimelb.edu.au.; Melbourne Brain Centre, 245 Burgundy Street, Heidelberg, VIC, 3084, Australia. emilio.perucca@unimelb.edu.au., Bialer M; Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.; David R. Bloom Center for Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel., White HS; Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.

Publikováno v: CNS drugs [CNS Drugs] 2023 Sep; Vol. 37 (9), pp. 755-779. Date of Electronic Publication: 2023 Aug 21.